ABSTRACT
Atypical food intake is a primary cause of obesity and other eating and metabolic disorders. Insight into the neural control of feeding has previously focused mainly on signalling mechanisms associated with the hypothalamus, the major centre in the brain that regulates body weight homeostasis. However, roles of non-canonical central nervous system signalling mechanisms in regulating feeding behaviour have been largely uncharacterized. Acetylcholine has long been proposed to influence feeding owing in part to the functional similarity between acetylcholine and nicotine, a known appetite suppressant. Nicotine is an exogenous agonist for acetylcholine receptors, suggesting that endogenous cholinergic signalling may play a part in normal physiological regulation of feeding. However, it remains unclear how cholinergic neurons in the brain regulate food intake. Here we report that cholinergic neurons of the mouse basal forebrain potently influence food intake and body weight. Impairment of cholinergic signalling increases food intake and results in severe obesity, whereas enhanced cholinergic signalling decreases food consumption. We found that cholinergic circuits modulate appetite suppression on downstream targets in the hypothalamus. Together our data reveal the cholinergic basal forebrain as a major modulatory centre underlying feeding behaviour.
Subject(s)
Appetite Regulation/physiology , Basal Forebrain/cytology , Basal Forebrain/physiology , Cholinergic Neurons/metabolism , Feeding Behavior/physiology , Satiety Response/physiology , Acetylcholine/metabolism , Animals , Body Weight/physiology , Cell Death , Choline O-Acetyltransferase/deficiency , Cholinergic Agonists , Cholinergic Neurons/pathology , Eating/physiology , Eating/psychology , Feeding Behavior/psychology , Female , Homeostasis , Hyperphagia/enzymology , Hyperphagia/genetics , Hyperphagia/pathology , Hypothalamus/cytology , Hypothalamus/physiology , Male , Mice , Mice, Knockout , Models, Neurological , Nicotine/metabolism , Obesity/enzymology , Obesity/genetics , Obesity/pathology , Receptors, Cholinergic/metabolismABSTRACT
Glioblastoma (GBM) is the least treatable type of brain tumor, afflicting over 15,000 people per year in the United States. Patients have a median survival of 16 months, and over 95% die within 5 years. The chemokine receptor ACKR3 is selectively expressed on both GBM cells and tumor-associated blood vessels. High tumor expression of ACKR3 correlates with poor prognosis and potential treatment resistance, making it an attractive therapeutic target. We engineered a single chain FV-human FC-immunoglobulin G1 (IgG1) antibody, X7Ab, to target ACKR3 in human and mouse GBM cells. We used hydrodynamic gene transfer to overexpress the antibody, with efficacy in vivo. X7Ab kills GBM tumor cells and ACKR3-expressing vascular endothelial cells by engaging the cytotoxic activity of natural killer (NK) cells and complement and the phagocytic activity of macrophages. Combining X7Ab with TMZ allows the TMZ dosage to be lowered, without compromising therapeutic efficacy. Mice treated with X7Ab and in combination with TMZ showed significant tumor reduction by MRI and longer survival overall. Brain-tumor-infiltrating leukocyte analysis revealed that X7Ab enhances the activation of M1 macrophages to support anti-tumor immune response in vivo. Targeting ACKR3 with immunotherapeutic monoclonal antibodies (mAbs) in combination with standard of care therapies may prove effective in treating GBM.
Subject(s)
Antibodies, Monoclonal/pharmacology , Glioblastoma/immunology , Glioblastoma/metabolism , Receptors, CXCR/antagonists & inhibitors , Temozolomide/pharmacology , Animals , Antibodies, Monoclonal/metabolism , Antibody Affinity/immunology , Antineoplastic Agents, Immunological/pharmacology , Cell Line, Tumor , Cytotoxicity, Immunologic/drug effects , Disease Models, Animal , Drug Synergism , Glioblastoma/diagnosis , Glioblastoma/mortality , Humans , Magnetic Resonance Imaging , Mice , Mortality , Protein Binding/immunology , Receptors, CXCR/metabolism , Xenograft Model Antitumor AssaysABSTRACT
Reactive astrocytes are associated with every form of neurological injury. Despite their ubiquity, the molecular mechanisms controlling their production and diverse functions remain poorly defined. Because many features of astrocyte development are recapitulated in reactive astrocytes, we investigated the role of nuclear factor I-A (NFIA), a key transcriptional regulator of astrocyte development whose contributions to reactive astrocytes remain undefined. Here, we show that NFIA is highly expressed in reactive astrocytes in human neurological injury and identify unique roles across distinct injury states and regions of the CNS. In the spinal cord, after white matter injury (WMI), NFIA-deficient astrocytes exhibit defects in blood-brain barrier remodeling, which are correlated with the suppression of timely remyelination. In the cortex, after ischemic stroke, NFIA is required for the production of reactive astrocytes from the subventricular zone (SVZ). Mechanistically, NFIA directly regulates the expression of thrombospondin 4 (Thbs4) in the SVZ, revealing a key transcriptional node regulating reactive astrogenesis. Together, these studies uncover critical roles for NFIA in reactive astrocytes and illustrate how region- and injury-specific factors dictate the spectrum of reactive astrocyte responses.
Subject(s)
Astrocytes/metabolism , Astrocytes/pathology , Central Nervous System/injuries , Central Nervous System/metabolism , NFI Transcription Factors/metabolism , Adult , Animals , Blood-Brain Barrier , Cell Differentiation , Central Nervous System/pathology , Humans , Mice , Mice, Knockout , Multiple Sclerosis/metabolism , Multiple Sclerosis/pathology , NFI Transcription Factors/deficiency , NFI Transcription Factors/genetics , Oligodendroglia/metabolism , Oligodendroglia/pathology , Remyelination , Stroke/metabolism , Stroke/pathology , Thrombospondins/genetics , Thrombospondins/metabolismABSTRACT
Long-range enhancer interactions critically regulate gene expression, yet little is known about how their coordinated activities contribute to CNS development or how this may, in turn, relate to disease states. By examining the regulation of the transcription factor NFIA in the developing spinal cord, we identified long-range enhancers that recapitulate NFIA expression across glial and neuronal lineages in vivo. Complementary genetic studies found that Sox9-Brn2 and Isl1-Lhx3 regulate enhancer activity and NFIA expression in glial and neuronal populations. Chromatin conformation analysis revealed that these enhancers and transcription factors form distinct architectures within these lineages in the spinal cord. In glioma models, the glia-specific architecture is present in tumors, and these enhancers are required for NFIA expression and contribute to glioma formation. By delineating three-dimensional mechanisms of gene expression regulation, our studies identify lineage-specific chromatin architectures and associated enhancers that regulate cell fate and tumorigenesis in the CNS.
Subject(s)
Carcinogenesis/genetics , Gene Expression Regulation, Neoplastic , Glioma/genetics , NFI Transcription Factors/genetics , Neuroglia/physiology , Animals , Base Sequence , Carcinogenesis/metabolism , Carcinogenesis/pathology , Chick Embryo , Female , Glioma/metabolism , Glioma/pathology , Male , Mice , Mice, Knockout , Mice, Transgenic , NFI Transcription Factors/biosynthesis , Neuroglia/pathology , Spinal Cord/growth & development , Spinal Cord/metabolism , Spinal Cord/pathologyABSTRACT
The safe and efficacious delivery of membrane impermeable therapeutics requires cytoplasmic access without the toxicity of nonspecific cytoplasmic membrane lysis. We have developed a mechanism for control of cytoplasmic release which utilizes endogenous proteases as a trigger and results in functional delivery of small interfering RNA (siRNA). The delivery approach is based on reversible inhibition of membrane disruptive polymers with protease-sensitive substrates. Proteolytic hydrolysis upon endocytosis restores the membrane destabilizing activity of the polymers thereby allowing cytoplasmic access of the co-delivered siRNA. Protease-sensitive polymer masking reagents derived from polyethylene glycol (PEG), which inhibit membrane interactions, and N-acetylgalactosamine, which targets asialoglycoprotein receptors on hepatocytes, were synthesized and used to formulate masked polymer-siRNA delivery vehicles. The size, charge and stability of the vehicles enable functional delivery of siRNA after subcutaneous administration and, with modification of the targeting ligand, have the potential for extrahepatic targeting.
Subject(s)
Factor VII/genetics , Gene Transfer Techniques , Peptide Hydrolases/metabolism , RNA, Small Interfering/administration & dosage , Animals , Erythrocytes/drug effects , Female , Hemolysis/drug effects , Macaca fascicularis , Male , Mice, Inbred ICR , Polymers/chemistry , RNA, Small Interfering/chemistry , RatsABSTRACT
A new tunable luminescent family of heterocyclic aromatic compounds containing boron has been prepared and characterized through NMR spectroscopy, mass spectrometry, absorption and fluorescence spectroscopy as well as structural study using single crystal X-ray crystallography. Spectroscopic properties of the new compounds were also studied using DFT and TDDFT computational models that showed very good agreement of the theoretical data with experimental results. Through introduction of auxochromic atoms such as sulfur and extension of the π system of the ligands it is possible to cover a large range of the visible spectrum. Activation and enhancement of the luminescence is achieved by condensation reactions that introduce the boron fragment forming stable, sublimable compounds suitable for OLED applications.